NASDAQ · LGVNHealthcarePharmaceuticals

Longeveron financials

$2.72+3.42%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
Revenue$1.2M$2.4M$709.0K$1.2M$1.3M
Gross profit$803.0K$1.9M$221.0K$497.0K$590.0K
Gross margin67.0%78.8%31.2%40.7%45.2%
Operating income-$23.3M-$16.5M-$21.0M-$18.0M-$17.5M
Net income-$22.7M-$24.6M-$22.2M-$18.8M-$17.0M
Net margin−1893.6%−1029.4%−3132.7%−1541.3%−1305.1%
Diluted EPS$-12.90$-26.20$-102.20$-90.00$-90.00
EBITDA-$22.1M-$15.6M-$20.1M-$17.1M-$16.5M
Operating cash flow-$18.6M-$13.9M-$19.0M-$14.0M-$19.1M
Free cash flow-$18.9M-$14.5M-$19.3M-$14.5M-$19.4M
Diluted shares1.8M0.9M0.2M0.2M0.2M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$4.7M$19.2M$4.9M$10.5M$25.7M
Short-term investments$0.00$0.00$412.0K$9.2M$9.4M
Total debt$0.00$0.00$0.00$0.00$1.2M
Total assets$10.3M$25.6M$12.1M$27.4M$42.8M
Total liabilities$4.6M$3.7M$5.3M$6.9M$5.3M
Shareholders' equity$5.7M$21.9M$6.7M$20.5M$37.5M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology